Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

On April 27, 2026 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, reported that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation:

Title: Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293
Summary: SG293 represents a differentiated approach for enabling potent and precise in vivo CAR T therapy for both oncology and autoimmune indications, potentially avoiding key off-target concerns.
Session: Advancing in vivo gene delivery with non-AAV viral vector systems
Session Location: MCEC Room 257AB (Level 2)
Session Date/Time: Tuesday, May 12, 2026; 8:00 – 9:45 a.m. ET
Presentation Time: 8:15 – 8:30 a.m. ET
Abstract Number: 20

The ASGCT (Free ASGCT Whitepaper) abstract is available to the public at: View Source

About SG293
SG293, which uses Sana’s proprietary fusogen-based delivery technology, is a CD8-targeted fusosome that delivers to CD8+ T cells the genetic material to make CD19-directed CAR T cells while avoiding potentially troublesome delivery to tissues such as the liver. The fusogen technology is designed to enable cell-specific delivery of material that integrates into the DNA of the target cell. Sana intends to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases.

(Press release, Sana Biotechnology, APR 27, 2026, View Source [SID1234664804])